BI-671800 is primarily used in research settings as a selective antagonist for the EP2 receptor, which is a subtype of the prostaglandin E2 receptor. Its application is significant in the study of inflammatory diseases, as blocking EP2 can help reduce inflammation and related symptoms. Researchers utilize BI-671800 to investigate its potential therapeutic effects in conditions such as asthma, chronic obstructive pulmonary disease (COPD), and other inflammatory disorders. Additionally, it serves as a tool to better understand the role of the EP2 receptor in various physiological and pathological processes, aiding in the development of targeted treatments.